• Users Online: 88
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 7  |  Issue : 3  |  Page : 103-108

Drug Interactions Between COVID-19 and Psychiatric Medications: A Mini Review


Department of Psychiatry, Health Sciences University Erenkoy Research and Training Hospital for Psychiatry and Neurological Diseases, Istanbul, Turkey

Correspondence Address:
Filiz Kulacaoglu
19 Mayis Mah. Sinan Ercan caddesi No: 19, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jnbs.jnbs_16_20

Rights and Permissions

Coronavirus disease 2019 (COVID-19) has become a pandemic with 8,708,000 confirmed cases and 461,715 death in the world until June 21, 2020. The Severe Acute Respiratory Syndrome Coronavirus 2 virus, which is an enveloped and single-stranded RNA virus belonging to Coronaviridea family, causes multiple organ systems diseases such as respiratory, gastrointestinal, hepatic, and neurological tracts in humans and animals. With the rapid and global spread of COVID-19, the scientific authorities have developed treatment algorithms for COVID-19. Besides the supportive care, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, tocilizumab, azithromycin, Vitamin C, and convalescent plasma therapy are frequently used off-label to treat COVID-19. For severe COVID-19 cases, the US Food and Drug Administration has issued an Emergency Use Authorization Remdesivir, which is the first drug to earn the title. COVID-19 treatment may cause many side effects and drug interactions. Psychiatric diseases are also chronic diseases, and psychiatric drugs may have severe interactions with COVID-19 medications. Drug interactions with psychiatric medication and neuropsychiatric side effects should be considered within the action mechanism of COVID-19 treatments. Thus, in this review, we aimed to elucidate the interactions of COVID-19 medications with the antidepressants, antipsychotics, and the other psychotropic drugs that have been frequently used in psychiatric diseases. Chloroquine, hydroxychloroquine, azithromycin, ribavirin, and lopinavir/ritonavir have interactions with psychiatric medications such as antidepressants, antipsychotics, anticonvulsants, and anxiolytics in terms of QTc interval prolongation, hepatotoxicity, myelosuppression, increased or decreased concentration of medications. Remdesivir has lower interactions with most of the psychiatric drugs except St John's Wort and some anticonvulsants. However, favipiravir is considered as the COVID-19 medication, which has lower interaction and side effects in combination with psychiatric medication. The use of tocilizumab is also safe with most of the psychiatric drugs and has a positive effect on depressive symptoms, although there is a risk of hepatotoxicity.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2202    
    Printed118    
    Emailed0    
    PDF Downloaded148    
    Comments [Add]    

Recommend this journal